Urogen Pharma Ltd (URGN) Stock Analysis
Verdict: HOLD
Blockbuster potential for UGN-102 drives momentum, but sustained profitability remains a 2027 story contingent on zero regulatory delays.
Investment score: 64/100
Analysis as of
Is Urogen Pharma Ltd stock worth reviewing? The TradeMates thesis
UroGen is transitioning from a niche player to a major uro-oncology contender, backed by 53% revenue growth and a high-probability Phase 3 pipeline. While current losses are steep, the consensus $1.49 EPS projection for 2027 makes the current $45.60 price look attractive for those willing to endure high volatility.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Urogen Pharma Ltd opportunities and risks
What speaks for URGN
- UGN-102 Commercial Launch
What speaks against URGN
- Binary Regulatory Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| URGN | n/a | 11.8x | n/a | 90.8% | -51.7% | -9.2% |
| KMDA | 20.2x | 2.3x | 10.2x | 41.2% | 11.2% | 4.0% |
| CGEN | 6.1x | 2.9x | 6.0x | 86.9% | 47.6% | 0.0% |
| ENTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.9% |
| Peer median | 6.1x | 2.3x | 6.0x | 41.2% | 11.2% | 0.0% |
Frequently asked questions about Urogen Pharma Ltd (URGN)
Is URGN stock a good investment?
The TradeMates model rates Urogen Pharma Ltd as HOLD with an investment score of 64/100. UroGen is transitioning from a niche player to a major uro-oncology contender, backed by 53% revenue growth and a high-probability Phase 3 pipeline. While current losses are steep, the consensus $1.49 EPS projection for 2027 makes the current $45.60 price look attractive for those willing to endure high volatility. This is algorithmic model output, not personal investment advice.
Is URGN stock a buy?
The TradeMates model verdict for URGN is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.